Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant.

Read the whole article on Physorg

More from Physorg